Phillip Md Et Al Frost Buys 67,434 Shares of OPKO Health, Inc. (NASDAQ:OPK) Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 67,434 shares of the business’s stock in a transaction on Friday, February 28th. The shares were purchased at an average price of $1.71 per share, with a total value of $115,312.14. Following the completion of the purchase, the chief executive officer now owns 213,301,448 shares in the company, valued at approximately $364,745,476.08. This trade represents a 0.03 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Tuesday, January 28th, Phillip Md Et Al Frost purchased 47,537 shares of OPKO Health stock. The shares were purchased at an average price of $1.47 per share, with a total value of $69,879.39.
• On Friday, January 17th, Phillip Md Et Al Frost purchased 150,000 shares of OPKO Health stock. The shares were purchased at an average price of $1.47 per share, with a total value of $220,500.00.
• On Wednesday, January 15th, Phillip Md Et Al Frost purchased 500,000 shares of OPKO Health stock. The shares were purchased at an average price of $1.48 per share, with a total value of $740,000.00.
• On Friday, December 13th, Phillip Md Et Al Frost purchased 125,000 shares of OPKO Health stock. The shares were purchased at an average price of $1.59 per share, with a total value of $198,750.00.
• On Wednesday, December 11th, Phillip Md Et Al Frost purchased 500,000 shares of OPKO Health stock. The shares were purchased at an average price of $1.56 per share, with a total value of $780,000.00.

OPKO Health Trading Up 6.7 %

Shares of NASDAQ:OPK opened at $1.74 on Friday. The stock has a 50 day moving average of $1.55 and a 200 day moving average of $1.55. The company has a market cap of $1.19 billion, a PE ratio of -9.16 and a beta of 1.63. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. OPKO Health, Inc. has a 12-month low of $0.86 and a 12-month high of $1.84.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.09. The company had revenue of $183.60 million during the quarter, compared to the consensus estimate of $155.42 million. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. As a group, equities research analysts expect that OPKO Health, Inc. will post -0.25 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in OPK. FMR LLC lifted its holdings in OPKO Health by 103.6% in the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 11,089 shares in the last quarter. Orion Portfolio Solutions LLC purchased a new position in OPKO Health in the 3rd quarter worth approximately $45,000. Cibc World Markets Corp purchased a new position in OPKO Health in the 4th quarter worth approximately $45,000. Zacks Investment Management purchased a new position in OPKO Health in the 4th quarter worth approximately $49,000. Finally, Ieq Capital LLC purchased a new position in OPKO Health in the 4th quarter worth approximately $52,000. 64.63% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

OPK has been the subject of a number of recent research reports. StockNews.com downgraded OPKO Health from a “hold” rating to a “sell” rating in a research note on Wednesday, January 15th. HC Wainwright reiterated a “buy” rating and set a $3.00 price objective on shares of OPKO Health in a research note on Wednesday, January 8th. Finally, Barrington Research reiterated an “outperform” rating and set a $2.25 price objective on shares of OPKO Health in a research note on Friday.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.